An experienced molecular cell biologist is sought to generate expression systems for human cytochrome P450 enzymes (CYPs) in human cells, as part of the company's new product development programme. This position will be predominantly laboratory-based in the first instance and is initially part-funded by a grant from the Technology Strategy Board, but represents a potential for a future leadership role within the company. Understanding of the commercial aspects of the company's growth will become essential. This role represents an exciting opportunity for a motivated and ambitious scientist to become part of a small and dynamic team.
The successful applicant will report directly to the company's Founder and CSO, Prof. Bob Chaudhuri.
An ideal candidate will have acquired experience in the use of BacMam technology for protein expression in mammalian cells and have expertise in molecular biology (proven experience in rapid cloning of DNA fragments in expression vectors, using ligase-dependent ligations, being essential), cell culture, cell biology and biochemistry. A PhD in an appropriate biological subject would be expected, but consideration will be given to applicants who have acquired the necessary experience elsewhere, particularly within industry. You must be eligible to work in the UK. Key attributes include:
CYP Design Ltd is a young and vibrant biotech company headquartered in Leicester developing new products and services for the global drug discovery industry. The company has developed proprietary technology for the expression of human CYPs in yeast, and their subsequent stabilisation, allowing transport and storage at ambient temperature. We expect to see significant growth through a milestone driven strategy and global diversification. As we expand, we will bring on a plethora of exceptional talent to help us further extend our manufacturing and marketing capabilities. These talented people will help us to diversify our product lines, enabling us to become the global leader for CYP-based products and services.
Making an Application
This is an excellent opportunity to join a fast growing ambitious organisation with a very exciting and busy future. Salary will depend on experience and on completion of the probationary period. There are also great training and career development opportunities within the company if your ability is proven. We can offer a varied and interesting working environment and we are focused on recognition and empowerment of our scientists and operational team. Relocation packages are not being offered. This position is available immediately. To apply, please send a CV and covering letter (stating the job reference number CDL-03 and your current salary) to email@example.com by 25th March 2014. Interviews will take place as soon as possible thereafter.
CYPDESIGN is pleased to announce that it has completed a Â£325k seed funding round led by Gask Consulting under the Enterprise Investment Scheme (SEIS). As part of the EIS round, Mercia Fund Management also followed its earlier SEIS investment.
CYPDESIGN is delighted to announce that it has been given the Start-Up of the Year award at the Medilink East Midlands Innovation Day Business Awards in Leicester on 11th June 2014.
CYPDESIGN has been awarded a grant by the government-backed Technology Strategy Board - the UK's innovation agency - to help support the development of new products and services, based on cytochrome P450s (CYPs).
Full Press Release available
CYPDESIGN is seeking to purchase or rent a lyophiliser with temperature-controlled shelves to develop its in-house production process for the manufacture of stabilised, dry films of sensitive membrane-bound enzymes. A research laboratory-scale instrument is required at this stage.
CYPDESIGN has been awarded funding by the UK Defence Science and Technology Laboratory's (Dstl) Centre for Defence Enterprise (CDE) for research designed to validate an automated platform for the discovery of safe, effective, broad-spectrum anti-bacterial compounds.
Full Press Release Available:
CYPDESIGN is pleased to announce that it has completed a seed funding round led by Mercia Fund Management Ltd (MFM) under the Seed Enterprise Investment Scheme (SEIS). As part of the SEIS round, the founders Prof Bob Chaudhuri, Dr Bill Primrose and Dr Paul Rodgers have been joined by Mr David Gask, a leading entrepreneur, as Chairman of the Board.
Full Press Release Available:-
CYPDESIGN presented its technology in the Innovation Zone of the ELRIG DD Conference in Manchester Central. We exhibited our products for metabolism and toxicity testing in Booth IZ4.
CYPDESIGN published an article in 'Industrial Pharmacy' entitled "Stable Cytochorme P450 Enzymes for Toxicity and Metabolism Testing". See Industrial Pharmacy, June 2013, Issue 38, pages 4 - 7
CYPDESIGN presented in the 'Platform & Diagnostics' Session of the 10th Anniversary EPIC Biotechnology Conference at the King's Fund in London on Thursday 6th June 2013.
CYPDESIGN was a finalist in the Royal Society of Chemistry's Emerging Technologies Competition, held in the Chemistry Centre, Piccadilly, London on Wednesday 5th June 2013.
CYPDESIGN attended BioWales 2013 at the Wales Millennium Centre, Cardiff
CYPDESIGN exhibited its unique stabilised cytochrome P450 products in the New Technology Showcase at the ELRIG Research and Innovation meeting in Telford